4//SEC Filing
Darazsdi Daniel G 4
Accession 0001412292-11-000004
CIK 0001003124other
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 9:07 AM ET
Size
28.3 KB
Accession
0001412292-11-000004
Insider Transaction Report
Form 4
Darazsdi Daniel G
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Options (to buy)
2011-12-05−62,104→ 0 totalExercise: $20.45→ Common Stock (62,104 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−62,104→ 0 totalExercise: $25.74→ Common Stock (62,104 underlying) - Discretionary Transaction
Common Stock
2011-11-22$24.98/sh+323$8,069→ 13,195 total - Disposition to Issuer
Common Stock
2011-12-05$33.25/sh−13,195$438,734→ 0 total - Disposition to Issuer
Stock Options (to buy)
2011-12-05−45,000→ 0 totalExercise: $27.27→ Common Stock (45,000 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−23,289→ 0 totalExercise: $19.94→ Common Stock (23,289 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−93,156→ 0 totalExercise: $34.15→ Common Stock (93,156 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−30,000→ 0 totalExercise: $26.64→ Common Stock (30,000 underlying) - Disposition to Issuer
Restricted Stock Units
2011-12-05−15,000→ 0 total→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−23,289→ 0 totalExercise: $37.69→ Common Stock (23,289 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−46,578→ 0 totalExercise: $43.26→ Common Stock (46,578 underlying)
Footnotes (8)
- [F1]Includes shares acquired under the automatic dividend reinvestment provision of the Company's Employee Stock Purchase Plan.
- [F2]Pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Prodcut Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger"), each of these shares of common stock was automatically converted into the right to receive $33.25.
- [F3]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 6/17/11, 6/17/12 and 6/17/13 but vesting was accelerated due to the Merger.
- [F4]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/23/12,2/23/13 and 2/23/14 but vesting was accelerated due to the Merger.
- [F5]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/25/11, 2/25/12 and 2/25/13 but vesting was accelerated due to the Merger.
- [F6]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/18/10, 2/18/11 and 2/18/12 but vesting was accelerated due to the Merger.
- [F7]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.
- [F8]Each restricted stock unit (RSU) represents a contingent right to receive one share of PPDI common stock. The RSUs were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but became fully vested pursuant to the terms of the Agreement. The RSUs were disposed of pursuant to the terms of the Agreement in exchange for a cash payment of $33.25 per share upon the effective date of the Merger.
Documents
Issuer
PHARMACEUTICAL PRODUCT DEVELOPMENT INC
CIK 0001003124
Entity typeother
Related Parties
1- filerCIK 0001412292
Filing Metadata
- Form type
- 4
- Filed
- Dec 5, 7:00 PM ET
- Accepted
- Dec 6, 9:07 AM ET
- Size
- 28.3 KB